U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H36F3N3O2
Molecular Weight 455.5567
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MK-0812

SMILES

[H][C@]1(CC[C@](CN2CCC3=C(C2)C=C(C=N3)C(F)(F)F)(C1)C(C)C)N[C@H]4CCOC[C@H]4OC

InChI

InChIKey=UNVWTBOGMHPKJM-CWKRKGSWSA-N
InChI=1S/C24H36F3N3O2/c1-16(2)23(7-4-19(11-23)29-21-6-9-32-14-22(21)31-3)15-30-8-5-20-17(13-30)10-18(12-28-20)24(25,26)27/h10,12,16,19,21-22,29H,4-9,11,13-15H2,1-3H3/t19-,21+,22-,23-/m1/s1

HIDE SMILES / InChI
MK-0812 is a potent and selective CCR2 antagonist, which was developed by Merck. This drug has entered clinical trials for both rheumatoid arthritis and multiple sclerosis. However, the rheumatoid arthritis trial was terminated because of lack of favorable outcomes when MK-0812 failed to show any early clinical improvement. The outcome of the multiple sclerosis trial of MK-0812 also had negative outcomes.

Originator

Curator's Comment: # Merck Research Laboratories

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

MK0812 once daily for 12 weeks
Route of Administration: Oral
MK0812 inhibited the binding of 125I-labeled recombinant human CCL2 to CCR2-containing mouse cell membranes with an IC50 of 19 nM in the presence of 97% mouse plasma. Similarly, MK0812 potently inhibited CCL2-mediated chemotaxis of WEHI-274.1 cells with an IC50 = 5 nM in the presence of 99% mouse plasma. The inhibition of WeHi-274.1 cell chemotaxis was tested with the concentrations of MK0812 (0.3 – 300 nM).
Name Type Language
MK-0812
Common Name English
MK0812
Common Name English
D-ERYTHRO-PENTITOL, 1,5-ANHYDRO-2,3-DIDEOXY-3-(((1R,3S)-3-((7,8-DIHYDRO-3-(TRIFLUOROMETHYL)-1,6-NAPHTHYRIDIN-6(5H)-YL)CARBONYL)-3-(1-METHYLETHYL)CYCLOPENTYL)AMINO)-4-O-METHYL-
Common Name English
Code System Code Type Description
PUBCHEM
71587773
Created by admin on Sat Dec 16 04:17:19 GMT 2023 , Edited by admin on Sat Dec 16 04:17:19 GMT 2023
PRIMARY
EPA CompTox
DTXSID9047336
Created by admin on Sat Dec 16 04:17:19 GMT 2023 , Edited by admin on Sat Dec 16 04:17:19 GMT 2023
PRIMARY
CAS
624733-88-6
Created by admin on Sat Dec 16 04:17:19 GMT 2023 , Edited by admin on Sat Dec 16 04:17:19 GMT 2023
PRIMARY
FDA UNII
P3LKY4ZL5O
Created by admin on Sat Dec 16 04:17:19 GMT 2023 , Edited by admin on Sat Dec 16 04:17:19 GMT 2023
PRIMARY
SMS_ID
300000041496
Created by admin on Sat Dec 16 04:17:19 GMT 2023 , Edited by admin on Sat Dec 16 04:17:19 GMT 2023
PRIMARY
DRUG BANK
DB11990
Created by admin on Sat Dec 16 04:17:19 GMT 2023 , Edited by admin on Sat Dec 16 04:17:19 GMT 2023
PRIMARY